EYPT - EyePoint Pharmaceuticals, Inc.
NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. (“EyePoint” or the “Company”) (NASDAQ: EYPT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
GSK (NYSE: GSK - Get Free Report) and Eyepoint Pharmaceuticals (NASDAQ: EYPT - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, analyst recommendations and risk. Valuation and Earnings This table compares GSK and Eyepoint
NEW YORK, Oct. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. ("EyePoint" or the "Company") (NASDAQ: EYPT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. (“EyePoint” or the “Company”) (NASDAQ: EYPT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. ("EyePoint" or the "Company") (NASDAQ: EYPT).
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. (“EyePoint” or the “Company”) (NASDAQ: EYPT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Tax-loss selling is likely to lead these 20 stocks to become artificially depressed in the fourth quarter — and therefore good bets to bounce back in the new year
NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. ("EyePoint" or the "Company") (NASDAQ: EYPT).
WATERTOWN, Mass., Sept. 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employee as inducement award outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
Eyepoint Pharmaceuticals (NASDAQ: EYPT - Get Free Report) and Bristol Myers Squibb (NYSE: BMY - Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, risk, earnings, analyst recommendations, dividends and institutional ownership. Analyst Ratings This is a breakdown of
NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. (“EyePoint” or the “Company”) (NASDAQ: EYPT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
EyePoint, Inc. (EYPT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
RADNOR, Pa., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by EyePoint, Inc. (NASDAQ: EYPT) on behalf of investors who purchased or acquired EyePoint, Inc. securities and experienced significant financial losses.
NEW YORK, Sept. 10, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. ("EyePoint" or the "Company") (NASDAQ: EYPT).
EyePoint, Inc. (EYPT) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. (“EyePoint” or the “Company”) (NASDAQ: EYPT).
Investigation Alert: EyePoint, Inc. (EYPT) Investors are Encouraged to Contact Kessler Topaz Meltzer and Check, LLP PR Newswire
RADNOR, Pa., Sept. 6, 2026 /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by EyePoint, Inc. (NASDAQ: EYPT) on behalf of investors who purchased or acquired EyePoint, Inc. securities and experienced significant financial losses.
RADNOR, Pa., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by EyePoint, Inc. (NASDAQ: EYPT) on behalf of investors who purchased or acquired EyePoint, Inc. securities and experienced significant financial losses.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT PR Newswire